Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Curanex PharmaceuticalsCURX +7.43%12 EV-to-FCF is -0.19 as of Aug. 01, 2026. GuruFocus rates CURX with a GF Score™ of 12/100. Among 345 Biotechnology companies, Curanex Pharmaceuticals ranks worse than 289854.78% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Curanex Pharmaceuticals's Enterprise Value is $2.11 Mil.
Curanex Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-11.29 Mil. Therefore, Curanex Pharmaceuticals's EV-to-FCF for today is -0.19.
The historical rank and industry rank for Curanex Pharmaceuticals's EV-to-FCF or its related term are showing as below:
CURX'
s EV-to-FCF Range Over the Past 10 Years
Min: -0.19 Med: 0 Max: 0
Current: -0.19
CURX's EV-to-FCF is ranked worse than 100% of 345
companies
in the Biotechnology industry
Industry Median: 14.39
vs CURX: -0.19
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Curanex Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Curanex Pharmaceuticals's share price for today is $0.2052.
Curanex Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.272.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Curanex Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curanex Pharmaceuticals EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Curanex Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Curanex Pharmaceuticals's EV-to-FCF falls into.
Curanex Pharmaceuticals's current Enterprise Value is $2.11 Mil.
Curanex Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.29 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curanex Pharmaceuticals (CURX) has a EV-to-FCF of -0.19 as of Aug. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Curanex Pharmaceuticals and its competitors. According to the industry distribution chart, Curanex Pharmaceuticals ranks #999999 out of 345 companies in the Biotechnology industry.
Is Curanex Pharmaceuticals' EV-to-FCF too high?
Curanex Pharmaceuticals' current EV-to-FCF is -0.19. Based on the distribution chart, Curanex Pharmaceuticals ranks #999999 out of 345 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Curanex Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Curanex Pharmaceuticals' EV-to-FCF compare to DRMA and NCNA?
According to the Biotechnology industry distribution chart, Curanex Pharmaceuticals ranks #999999 out of 345 companies for EV-to-FCF. This places Curanex Pharmaceuticals in the lower half of its industry. The industry median EV-to-FCF is 14.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.39, based on 345 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Curanex Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curanex Pharmaceuticals's current EV-to-FCF is -0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curanex Pharmaceuticals stock overvalued right now?
Curanex Pharmaceuticals (CURX) has a current EV-to-FCF of -0.19. The current EV-to-FCF is -0.19. Curanex Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Curanex Pharmaceuticals (CURX), the current EV-to-FCF is -0.19 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.
12GF Score
Get the complete analysis for CURX
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CURX has been successfully added to your 
